Single-cell analysis of localized Ras-LOCKR-S demonstrated that a subpopulation of KRas-G12C-driven cancer cells treated with Ras-G12C–GDP inhibitors increased Golgi-localized WT H/NRas activity, which correlates with rebound MAPK signaling and drug-resistant cell growth. This evidence concerns the gene KRAS and cancer.